폐암 유전체 검사 시장 예측 : 산업 규모, 점유율, 동향, 기회, 구성요소별, 기술별, 패널 유형별, 샘플 유형별, 최종 사용자별, 지역별, 경쟁 구도(2021-2031년)
Lung Cancer Genomic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component, By Technology, By Panel Type, By Sample Type, By End User, By Region & Competition, 2021-2031F
상품코드:1901604
리서치사:TechSci Research
발행일:2026년 01월
페이지 정보:영문 183 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계 폐암 유전체 검사 시장은 2025년 21억 7,000만 달러, 2031년까지 37억 6,000만 달러에 달하고, CAGR은 9.59%를 나타낼 것으로 예측됩니다.
폐암 유전체 검사에서는 종양 조직 또는 액체 생검의 분자 해석을 실시하여 EGFR 변이나 ALK 재조합 등 특정 유전자 변이를 특정합니다. 이러한 돌연변이는 표적 요법의 선택을 결정하는 중요한 요소입니다. 본 시장의 성장은 주로 맞춤형 의료로의 임상적 전환과 신규 항암제의 사용을 승인하기 위한 동반진단약에 대한 엄격한 규제 요건에 의해 추진되고 있습니다.
시장 개요
예측 기간
2027-2031년
시장 규모 : 2025년
21억 7,000만 달러
시장 규모 : 2031년
37억 6,000만 달러
CAGR : 2026-2031년
9.59%
가장 빠르게 성장하는 부문
중합 효소 연쇄반응
가장 큰 시장
북미
주요 시장 성장 촉진요인
세계적으로 증가하는 폐암의 발생률 및 유병률은 유전체 검사 시장의 기반이 되는 추진력으로서 기능하여 정밀한 분자진단을 필요로 하는 환자층의 확대를 가져오고 있습니다. 폐악성 종양의 부담이 세계적으로 높은 수준에서 계속되고 있는 가운데, 헬스케어 시스템에서는 가장 효과적인 관리 전략을 결정하기 위해, 새롭게 진단된 모든 환자에 대한 종합적인 바이오마커 검사의 실시가 점점 의무화되고 있습니다.
주요 시장 과제
차세대 시퀀싱에 대한 상환 상황의 변동은 세계의 폐암 유전체 검사 시장의 성장을 저해하는 큰 장벽이 되고 있습니다. 임상 가이드라인에서는 종합적인 프로파일링이 점점 더 권장되고 있는 반면, 보험자의 통일적 적용 부족은 심각한 경제적 마찰을 초래하여 임상 가용성과 환자 접근성을 분리하고 있습니다.
주요 시장 동향
단일 유전자 검사에서 종합적인 차세대 시퀀싱(NGS) 패널로의 전환은 제한된 조직 샘플에서 여러 치료적 의미있는 돌연변이를 효율적으로 식별 할 필요성으로 폐 악성 종양의 진단 기준을 재구성합니다. 임상의는 조직의 고갈 위험이 있는 반복적인 단일 바이오마커 검사를 점차 포기하고, 단일 워크플로우에서 공동 돌연변이 및 종양 돌연변이 부하(TMB)와 같은 복잡한 서명을 포착하는 광범위한 유전체 프로파일링을 선택하는 경향이 커지고 있습니다.
The Global Lung Cancer Genomic Testing Market will grow from USD 2.17 Billion in 2025 to USD 3.76 Billion by 2031 at a 9.59% CAGR. Lung cancer genomic testing involves the molecular analysis of tumor tissue or liquid biopsies to identify specific genetic alterations such as EGFR mutations or ALK rearrangements that dictate the selection of targeted therapies. The market is primarily propelled by the clinical transition toward personalized medicine and the stringent regulatory requirement for companion diagnostics to authorize the use of novel oncology drugs.
Market Overview
Forecast Period
2027-2031
Market Size 2025
USD 2.17 Billion
Market Size 2031
USD 3.76 Billion
CAGR 2026-2031
9.59%
Fastest Growing Segment
Polymerase Chain Reaction
Largest Market
North America
Key Market Drivers
The Rising Global Incidence and Prevalence of Lung Cancer serves as the foundational catalyst for the genomic testing market, creating an expanding patient pool that necessitates precise molecular diagnosis. As the burden of lung malignancy remains high globally, healthcare systems are increasingly mandating comprehensive biomarker testing for all newly diagnosed patients to determine the most effective management strategies. This volume-driven demand is evidenced by the sheer scale of diagnoses in major markets.
Key Market Challenges
The inconsistent reimbursement landscape for next-generation sequencing constitutes a substantial barrier hampering the growth of the Global Lung Cancer Genomic Testing Market. While clinical guidelines increasingly recommend comprehensive profiling, the lack of uniform payer coverage creates severe economic friction that disconnects clinical availability from patient accessibility. Diagnostic developers face restricted revenue potential as healthcare providers often hesitate to order advanced genomic profiling due to uncertainty regarding payment authorization.
Key Market Trends
The transition from single-gene assays to comprehensive next-generation sequencing (NGS) panels is reshaping the diagnostic standard for lung malignancy, driven by the need to efficiently identify multiple actionable alterations from limited tissue samples. Clinicians are increasingly abandoning iterative single-biomarker testing, which risks tissue exhaustion, in favor of broad genomic profiling that captures co-occurring mutations and complex signatures like tumor mutational burden in a single workflow. This consolidation is critical for matching patients to the growing array of targeted therapies without the latency of sequential testing.
Key Market Players
QIAGEN NV
Agilent Technologies Inc.
Thermo Fisher Scientific Inc.
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings
CENTOGENE N.V.
BGI Genomics Co. Ltd.
CeGaT GmbH
Illumina Inc.
F. Hoffmann-La Roche Ltd
Report Scope:
In this report, the Global Lung Cancer Genomic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Lung Cancer Genomic Testing Market, By Component:
Products v/s Services
Lung Cancer Genomic Testing Market, By Technology:
Next Generation Sequencing
Polymerase Chain Reactions
Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH)
Others
Lung Cancer Genomic Testing Market, By Panel Type:
Single Panel v/s Multi-Gene Panel
Lung Cancer Genomic Testing Market, By Sample Type:
Tissue Biopsy v/s Liquid Biopsy
Lung Cancer Genomic Testing Market, By End User:
Academic & Research Institutions
Hospitals & Clinics
Diagnostic Laboratories
Others
Lung Cancer Genomic Testing Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Genomic Testing Market.
Available Customizations:
Global Lung Cancer Genomic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Lung Cancer Genomic Testing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Component (Products v/s Services)
5.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others)
5.2.3. By Panel Type (Single Panel v/s Multi-Gene Panel)
5.2.4. By Sample Type (Tissue Biopsy v/s Liquid Biopsy)
5.2.5. By End User (Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories, Others)
5.2.6. By Region
5.2.7. By Company (2025)
5.3. Market Map
6. North America Lung Cancer Genomic Testing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Component
6.2.2. By Technology
6.2.3. By Panel Type
6.2.4. By Sample Type
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Lung Cancer Genomic Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Component
6.3.1.2.2. By Technology
6.3.1.2.3. By Panel Type
6.3.1.2.4. By Sample Type
6.3.1.2.5. By End User
6.3.2. Canada Lung Cancer Genomic Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Component
6.3.2.2.2. By Technology
6.3.2.2.3. By Panel Type
6.3.2.2.4. By Sample Type
6.3.2.2.5. By End User
6.3.3. Mexico Lung Cancer Genomic Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Component
6.3.3.2.2. By Technology
6.3.3.2.3. By Panel Type
6.3.3.2.4. By Sample Type
6.3.3.2.5. By End User
7. Europe Lung Cancer Genomic Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Component
7.2.2. By Technology
7.2.3. By Panel Type
7.2.4. By Sample Type
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Lung Cancer Genomic Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Component
7.3.1.2.2. By Technology
7.3.1.2.3. By Panel Type
7.3.1.2.4. By Sample Type
7.3.1.2.5. By End User
7.3.2. France Lung Cancer Genomic Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Component
7.3.2.2.2. By Technology
7.3.2.2.3. By Panel Type
7.3.2.2.4. By Sample Type
7.3.2.2.5. By End User
7.3.3. United Kingdom Lung Cancer Genomic Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Component
7.3.3.2.2. By Technology
7.3.3.2.3. By Panel Type
7.3.3.2.4. By Sample Type
7.3.3.2.5. By End User
7.3.4. Italy Lung Cancer Genomic Testing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Component
7.3.4.2.2. By Technology
7.3.4.2.3. By Panel Type
7.3.4.2.4. By Sample Type
7.3.4.2.5. By End User
7.3.5. Spain Lung Cancer Genomic Testing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Component
7.3.5.2.2. By Technology
7.3.5.2.3. By Panel Type
7.3.5.2.4. By Sample Type
7.3.5.2.5. By End User
8. Asia Pacific Lung Cancer Genomic Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Component
8.2.2. By Technology
8.2.3. By Panel Type
8.2.4. By Sample Type
8.2.5. By End User
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Lung Cancer Genomic Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Component
8.3.1.2.2. By Technology
8.3.1.2.3. By Panel Type
8.3.1.2.4. By Sample Type
8.3.1.2.5. By End User
8.3.2. India Lung Cancer Genomic Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Component
8.3.2.2.2. By Technology
8.3.2.2.3. By Panel Type
8.3.2.2.4. By Sample Type
8.3.2.2.5. By End User
8.3.3. Japan Lung Cancer Genomic Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Component
8.3.3.2.2. By Technology
8.3.3.2.3. By Panel Type
8.3.3.2.4. By Sample Type
8.3.3.2.5. By End User
8.3.4. South Korea Lung Cancer Genomic Testing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Component
8.3.4.2.2. By Technology
8.3.4.2.3. By Panel Type
8.3.4.2.4. By Sample Type
8.3.4.2.5. By End User
8.3.5. Australia Lung Cancer Genomic Testing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Component
8.3.5.2.2. By Technology
8.3.5.2.3. By Panel Type
8.3.5.2.4. By Sample Type
8.3.5.2.5. By End User
9. Middle East & Africa Lung Cancer Genomic Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Component
9.2.2. By Technology
9.2.3. By Panel Type
9.2.4. By Sample Type
9.2.5. By End User
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Lung Cancer Genomic Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Component
9.3.1.2.2. By Technology
9.3.1.2.3. By Panel Type
9.3.1.2.4. By Sample Type
9.3.1.2.5. By End User
9.3.2. UAE Lung Cancer Genomic Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Component
9.3.2.2.2. By Technology
9.3.2.2.3. By Panel Type
9.3.2.2.4. By Sample Type
9.3.2.2.5. By End User
9.3.3. South Africa Lung Cancer Genomic Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Component
9.3.3.2.2. By Technology
9.3.3.2.3. By Panel Type
9.3.3.2.4. By Sample Type
9.3.3.2.5. By End User
10. South America Lung Cancer Genomic Testing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Component
10.2.2. By Technology
10.2.3. By Panel Type
10.2.4. By Sample Type
10.2.5. By End User
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Lung Cancer Genomic Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Component
10.3.1.2.2. By Technology
10.3.1.2.3. By Panel Type
10.3.1.2.4. By Sample Type
10.3.1.2.5. By End User
10.3.2. Colombia Lung Cancer Genomic Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Component
10.3.2.2.2. By Technology
10.3.2.2.3. By Panel Type
10.3.2.2.4. By Sample Type
10.3.2.2.5. By End User
10.3.3. Argentina Lung Cancer Genomic Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Component
10.3.3.2.2. By Technology
10.3.3.2.3. By Panel Type
10.3.3.2.4. By Sample Type
10.3.3.2.5. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Lung Cancer Genomic Testing Market: SWOT Analysis
